1. Saran R, Robinson B, Abbott KC, Bragg-Gresham J, Chen X, Gipson D, et al. US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2020;75(1 Suppl 1):A6-A7.
2. Zhang L, Zhao MH, Zuo L, Wang Y, Yu F, Zhang H, et al. China Kidney Disease Network (CK-NET) 2016 Annual Data Report. Kidney Int Suppl (2011). 2020;10(2):e97-e185.
3. Saran R, Robinson B, Abbott KC, Agodoa LYC, Bhave N, Bragg-Gresham J, et al. US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis. 2018;71(3 Suppl 1):A7.
4. Karkar A, Bouhaha BM, Dammang ML. Infection control in hemodialysis units: a quick access to essential elements. Saudi J Kidney Dis Transpl. 2014;25(3):496-519.
5. Wu YL, Zhang JJ, Li RJ, Cai CY, Zhang YH, Xu TM, et al. Prevalence of infections and antimicrobial use among hemodialysis outpatients: A prospective multicenter study. Semin Dial. 2020;33(2):156-162.
6. Nguyen DB, Shugart A, Lines C, Shah AB, Edwards J, Pollock D, et al. National Healthcare Safety Network (NHSN) Dialysis Event Surveillance Report for 2014. Clin J Am Soc Nephrol. 2017;12(7):1139-1146.
7. Ravani P, Palmer SC, Oliver MJ, Quinn RR, MacRae JM, Tai DJ, et al. Associations between hemodialysis access type and clinical outcomes: a systematic review. J Am Soc Nephrol. 2013;24(3):465-473.
8. Zhang H, Li L, Jia H, Liu Y, Wen J, Wu A, et al. Surveillance of Dialysis Events: one-year experience at 33 outpatient hemodialysis centers in China. Sci Rep. 2017;7(1):249.
9. Centers for Disease Control and Prevention: National Healthcare Safety Network: Dialysis Event Surveillance Protocol. 2019:https://www.cdc.gov/nhsn/dialysis/event/.
10. Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, et al. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis. 2013;62(5):849-859.
11. Abdelfattah RR, Al-Jumaah S, Al-Korbi L, Al-Qahtani T. Three years' experience of dialysis event surveillance. Am J Infect Control. 2019;47(7):793-797.
12. Schwanke AA, Danski MTR, Pontes L, Kusma SZ, Lind J. Central venous catheter for hemodialysis: incidence of infection and risk factors. Rev Bras Enferm. 2018;71(3):1115-1121.
13. Bohlke M, Uliano G, Barcellos FC. Hemodialysis catheter-related infection: prophylaxis, diagnosis and treatment. J Vasc Access. 2015;16(5):347-355.
14. Krishnan A, Irani K, Swaminathan R, Boan P. A retrospective study of tunnelled haemodialysis central line-associated bloodstream infections. J Chemother. 2019;31(3):132-136.
15. Borzou SR, Gholyaf M, Zandiha M, Amini R, Goodarzi MT, Torkaman B. The effect of increasing blood flow rate on dialysis adequacy in hemodialysis patients. Saudi J Kidney Dis Transpl. 2009;20(4):639-642.
16. Chang KY, Kim SH, Kim YO, Jin DC, Song HC, Choi EJ, et al. The impact of blood flow rate during hemodialysis on all-cause mortality. Korean J Intern Med. 2016;31(6):1131-1139.
17. Li Y, Xiao P, Wang Y, Hao Y. Mechanisms and Control Measures of Mature Biofilm Resistance to Antimicrobial Agents in the Clinical Context. ACS Omega. 2020;5(36):22684-22690.
18. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 2001;9(1):34-39.
19. Lucas TC, Tessarolo F, Jakitsch V, Caola I, Brunori G, Nollo G, et al. Blood flow in hemodialysis catheters: a numerical simulation and microscopic analysis of in vivo-formed fibrin. Artif Organs. 2014;38(7):556-565.
20. Satorius AE, Szafranski J, Pyne D, Ganesan M, Solomon MJ, Newton DW, et al. Complement c5a generation by staphylococcal biofilms. Shock. 2013;39(4):336-342.
21. Perez-Garcia R, Varas J, Cives A, Martin-Malo A, Aljama P, Ramos R, et al. Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis. Nephrol Dial Transplant. 2018;33(1):187.
22. Ogawa T, Nitta K. Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients. Contrib Nephrol. 2015;185:76-86.
23. Sakaguchi Y, Hamano T, Wada A, Masakane I. Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis. J Am Soc Nephrol. 2019;30(6):1037-1048.
24. Del Vecchio L, Locatelli F. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease. Expert Opin Investig Drugs. 2018;27(7):613-621.
25. Fujii H. [CKD-MBD and cardiovascular disease.]. Clin Calcium. 2019;29(2):179-184.